Why the study?
Does once-daily enoxaparin dosing improve target anti-Xa level attainment compared to twice-daily dosing in ACS patients with severe renal impairment?
Does once-daily enoxaparin dosing improve target anti-Xa level attainment compared to twice-daily dosing in ACS patients with severe renal impairment?
Once-daily dosing of enoxaparin is more effective than twice-daily dosing at achieving target trough anti-Xa levels in ACS patients with severe renal impairment.
No takes yet. Share an insight, caveat, or question.
Once-daily dosing was associated with higher target trough attainment in severe renal impairment; leaves open impact on clinical outcomes.
Jessica et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: